CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sinco Pharmaceuticals Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sinco Pharmaceuticals Holdings Ltd
E5-1805, Global Center, No. 1700
North Section of Tianfu Avenue, High-Tec
Phone: +86 2862912988p:+86 2862912988 CHENGDU, SIC  China Ticker: 68336833
Business Summary
Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board XiangbinHuang 56 3/29/2023 3/16/2015
Chief Executive Officer MinJin 44 3/29/2023 11/6/2020
Chief Financial Officer YifanLi 42 6/2/2015 6/2/2015
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 266 (As of 6/30/2023)
Outstanding Shares: 2,032,890,585 (As of 6/30/2023)
Stock Exchange: HKG
Fax Number: +86 2862912922


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024